Serum Beta-2-Microglobulin Levels in Urological Cancer
- 1 May 1979
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 121 (5) , 624-625
- https://doi.org/10.1016/s0022-5347(17)56910-4
Abstract
Serum beta-2-microglobulin levels were measured in patients with renal, vesical and prostatic cancer. Measurements were made only on samples with a serum creatinine less than or equal to 105/umol./l. to eliminate the possibility of elevated beta-2-microglobulin being a result of impaired renal function. This criterion eliminated 28 to 50 per cent of the patients with bladder cancer and 73 per cent of those who had undergone nephrectomy for renal carcinoma, which, obviously, limits the value of beta-2-microglobulin measurement for the surveillance in these cancers. Beta-2-microglobulin values in patients with prostatic cancer were seldom increased to more than 3.0 mg./l. In bladder cancer patients with normal serum creatinine the frequency of an elevated serum beta-2-microglobulin increased with the increase in tumor stage.This publication has 6 references indexed in Scilit:
- Serum β2-microglobulin in controls and cancer patientsClinica Chimica Acta; International Journal of Clinical Chemistry, 1977
- β2-Microglobulin levels in cancerous and other disease statesClinica Chimica Acta; International Journal of Clinical Chemistry, 1976
- Beta2Microglobulin and Lymphocytic Infiltration in Sjögren's SyndromeNew England Journal of Medicine, 1975
- Serum β2-Microglobulin in Renal DiseaseNephron, 1973
- The Serum Levels and Urinary Excretion of β2-Microglobulin in Apparently Healthy SubjectsScandinavian Journal of Clinical and Laboratory Investigation, 1972
- Differentiation of glomerular, tubular, and normal proteinuria: determinations of urinary excretion of β2-microglobulin, albumin, and total proteinJournal of Clinical Investigation, 1969